brobert
/
LogseqFMS
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity
You cannot select more than 25 topics Topics must start with a letter or number, can include dashes ('-') and can be up to 35 characters long.
master
Branches Tags
${ item.name }
Create tag ${ searchTerm }
Create branch ${ searchTerm }
from '4291717d7b'
${ noResults }
LogseqFMS/journals/2024_04_04.md

9.2 KiB
Raw Blame History

- # #Tareas - DONE PREPARAR presentación de María Santamaría SCHEDULED: <2024-04-04 Thu> - DONE [#A] PREPARAR presentación sobre las comunicaciones de STOP2030 para la reunión con el Advisory Board SCHEDULED: <2024-04-04 Thu> - DONE [#A] PREGUNTAR a Marina y Silvia si tienen claras algunas de las invitaciones que podríamos ir mandando ya para que yo vaya preparándolo SCHEDULED: <2024-04-04 Thu> - DONE ENTERARME de si hay reunión con Sonia y Dolores y Adela SCHEDULED: <2024-04-04 Thu> - DONE ACTUALIZAR lista de invitado al Evento con sugerencias de Marina SCHEDULED: <2024-04-04 Thu> - DONE ESCRIBIR a Chema Buceta para preguntarle qué tal van las gestiones con Caixaforum SCHEDULED: <2024-04-15 Mon> - DONE PEDIR Carteles para cribado de Chagas en el consulado el sábado 2024/05/04 a Scienseed SCHEDULED: <2024-04-10 Wed> DEADLINE: <2024-04-19 Fri> - CANCELED IR al cribado al consulado SCHEDULED: <2024-05-04 Sat> - DONE ESCRIBIR una nota sobre la primera reunión de STOP2030/STAB para la Web y circulársela a Alejandro Krolewiecki antes para que le dé el OK SCHEDULED: <2024-04-09 Tue> 
-

  • #Eventos

    • DONE 15:00 - 16:30: Reu equipo comunicaciones SCHEDULED: <2024-04-04 Thu 15:00> :AGENDA: estimated: 1h :END:
    • CANCELED 11:15 - 12:30: Presentación GEPI SCHEDULED: <2024-04-04 Thu>
    • CANCELED 13:00 - 14:00: Reunión Ade + Sonia + Dolores + Borja SCHEDULED: <2024-04-04 Thu 13:00>
    • DONE 16:00 - 17:00: STOP2030 - STAB Meeting SCHEDULED: <2024-04-04 Thu 16:00>

      • Notas STOP2030/STAB

        • AK. To begin with ty to them. To be part of the STAB meeting and being availsable at the same time. I prepared a presentation which wont take more than 20-25 mins an get your input. We really value this. Adhoc afiliation with Liconsa. Affiliation to FMS. Estuvo en previous stop durante el ALIVE study.
        • John Amuasi: physician. Global health infectious diseases and global health department.
        • Raj Shankar Gosh: mefico trained in public health: working onf infectious Climate health and resistance and the founder at a startup in Dehli
        • Denise Mupfasoni: NTD department at WHO leading all the STH related activities. Key stakeholder on our. Geneva. Member as an observer in this group. Not a full member.
        • Pat Lamie: task force for global health. Colleague on AK durante unos 20 años.
        • Collins Okoyo: Kenya. Leader of WP3 on modelling and cost effectiveness.
        • Julie: Bridges, we lead wp5. Excited to hear.
        • Marina: Anthropologist. WP5 with bridges more focused on the comms.
        • Carla Valribiera: coordinating all the consortium members
        • AK: stop 1 y stop2 querían hacer un pivotal trial de la fdc y show safety and efficacy against STH
        • Liconsa responsability.
        • Liconsa tiene track record en gloabl health porque hacen el benznidazol y han prequalified ivermectin.
        • ISGlobal lidership de las biomedical sciences.
        • WP3 leaded by KEMRI: leaded by modelling and db but also as a siste.
        • wp4: the social sciences: acceptabiility feasibility and adherence: also clinical site, but also a leader through their expertise on other projects on acceptaibility.
        • WP5: policty, access, advocacy and communications.
        • Y por último Sanger working on developing surveillance methods por genomic ana
        • The target of the consorcios es crear goals and evidence needed by WHO in evaluating the incorporating this strategies into programs.
        • We know that the FDC también es util para oncho, lf, scabies y demás pero tenemos que elegir una disease of particular interest to perform the particular studies. So far the achievements have been: submission to EMA through art 58. the main target is leading the way to prequalification to WHO. We did the pivotal trial that demonstrated safety efficacy against T. Trichiura.
        • Our current main challenges are safety and acceptability. We've had conversations with the department in Geneva to align our strategies.
        • Evaluation of implementation strategies, pathways to programs and an access plan.
        • We look for your expertise in these 3 aspects. Our interest is go beyond the science limited to STH and a vision of global health and a program of implementation.
        • TODO LEER 2030 targets for soil-transmitted helminthiases de WHO SCHEDULED: <2024-04-21 Sun>
        • Of particular interest where the ocular nosequé
        • El clinical trial is under review. Nothing to highlight regarding safety, which lead us to go to test safety with bigger populations.
        • consideramos lo de 3 dosis para situaciones que no son las de MDA sino otros escenarios.
        • For strongi we didn't reach the recruitement size. The answer we wanted to provide we couldnt give.
        • Our project is proposing an innovation with our fdc but also for other ways of getting ivm.
        • Safety, palatability and efficacy están demostrados
        • Generate the evidence and arguments to our policy and access planning communicating with the correct stakehoulders and provide us input and give visibility to the project.
        • El REALISE es en una zona endémica de T. trichiura. O alb o fdc una vez.
        • What type of acceptability studies are really needed to evaluate acceptabilty? End users or los jefes de los sistemas de salud? Either one, or both, can be the right target of these studies.
        • Our conclusions and proposal is revisit the dosign strategies for ivm.
        • Pat Lammie: A couple of questions: great presentation of the data generated. When you where looking at the reductions in egg with T. t. The scatter that you saw with fdc1 or fdc3. What is going in con la gente que no muestra esa reduction?
        • AK: We have hypothesis: people working in the vet world have shown that having a longer exposure to the drug improve the efficacy. We haven't completed the genomic analysis trying to identify if there is a difference. But the pharmacokinetic analysis shows in Phase II we couldn't identify. We only saw it in blood, not where the parasite is.
        • PL: The work being done by Sanger is it full genome analysis?
        • AK: sí. su approach también es ese para este proyecto.
        • JOHN AMUASI: really a rich presentation of the clinical data. Quite a significant variation in the AE.
        • AK: We did find larger number of individuals with AE. it was expected. All mild and moderate severity, all self limiting. Non of the participants in the FDC3 had to stop and not take all the doses.
        • AK. Differences por zona. Some hypothesis: the main one es que en algunas zonas tienen más acceso a medicinas?
        • AK. We didn't find the AE were not age sensitive. but eventhough our inclusion criteria had from 5 to 17 years old, most where 6-11. We couldn't identify any trends. In the smaller group in the phase. Tampoco para antropometric ni nada así. Lo único fue el trial site.
        • JA: Site differences might mean there is site noise?
        • JULIE: los programs son muy safe y se llevan haciendo décadas. he biggest safety issue is chocking. Oro dispersable mango flavoured. The program siempre se ha basado en uan fixed dose. IVM can be very difficult.
        • RAJ: one of the principal concerns that I have heard was around the number of tablets and chocking, and this is really solved by this. Integration of this program into the current programs STH in teh countries or new ones? We might need to think aobut it. Are there any plans to do economic evaluations? The larger impact of this fdc and reduced number of tablets have we thought about would be the requirement for the capacity building for frontline workers and so on?
        • AK: Part of the ecnomic analisis lo ahcen los del london school de stop1 y 2. Hace falta algo más? we needed to have a leading indication to do the clinical trials. this could perfecly be used to LF. either program or country, in all the concepts where integrations could be used. We're not limiting our stakeholders to STH or NTD. this could go wider than that.
        • RAJ: integration is being used very loosely by many programs. Some use the word withgout providing the evidence. The program managers need to integrate this into the current programs.
        • DENISE: Come back on the integration. Alb and ivm has been distributed for a long time for LF and they work for STH. integration within the NTDs. Also scabies. also outside, in immunization programs can be includede because its a fixed dose. We have to think in countries where we don't have LF and dont have access to the donations of ivm. In a country where we have people with obesity is FDC good?
        • AK: uno con 9mg y otro con 18mg. A person up to 90kg would recieve 200ug/kg
        • AK: 2 key comments. confidentiality agreement. This was the initial meeting, the introduction and background and overall goals. We need to check the frequency of our meetings. We'll me doings some proposals for the minutes. Take less presentations and more oportunity to talk.

  • Cosas de gastos del Evento

    • Sala, catering, técnicos (Caixaforum)
    • Sala NH, comida NH
    • Chema Buceta
      • Se encarga de la relación con Caixaforum
      • Se encarga de la visita a Liconsa/Chemo/nosecual
    • Comida CA
    • Scienseed
      • Buscar cuántas horas han metido al evento
      • Me dio autorización (informal) Marina a decirles que si necesitan facturar algo por fuera lo hagan